Cipla rolls out generic version of remedisvir

Welcome Guest! You are here: Home » Health

Cipla rolls out generic version of remedisvir

Cipla will provide training on use of the drug, inform patient consent documents, conduct post marketing surveillance

Sunday June 21, 2020 10:43 PM, IANS

Mumbai: Drug maker Cipla Limited on Sunday announced the launch of experimental anti-viral drug remdesivir under its brand name Cipremi. Remdesivir is the only US FDA approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalized with suspected or laboratory confirmed COVID-19 infection.

In May, US drug maker Gilead Sciences extended a voluntary non-exclusive license to Cipla to manufacture and market Cipla's generic version of remedisvir called Cipremi.

'Emergency Use'

The Drug Controller General of India (DCGI) has granted Cipla regulatory approval for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need, the company said in a statement.

As part of a risk management plan, Cipla will provide training on use of the drug, inform patient consent documents, conduct post marketing surveillance as well as conduct a Phase IV clinical trial on Indian patients.

Also Read | CIPLA, US Bullying, Indira Gandhi and Narendra Modi

"Cipla appreciates the strong partnership with Gilead to bring remdesivir to patients in India. We have been deeply invested in exploring all possible avenues to save millions of lives impacted by Covid-19 pandemic, and this launch is a significant milestone in that direction," said Umang Vohra MD and Global CEO, Cipla.

According to a preliminary report from the ACTT-1 (Adaptive COVID-19 Treatment Trial 1) study, a randomized clinical trial conducted with remdesivir on 1,063 patients over 60 centres across US, Europe and Asia demonstrated a faster time to clinical recovery in hospitalised patients as compared to placebo.

Most of these patients were on oxygen therapy of which some were receiving high flow oxygen or non-invasive ventilation, and some were on a mechanical ventilator.

The mortality rates in the study were 7.1 per cent in those given remdesivir and 11.9 per cent in those who were given placebo.

Agreements with six Indian pharmaceutical companies

In May, Gilead Sciences signed non-exclusive voluntary licensing agreements with six Indian pharmaceutical companies to boost the supply of remdesivir, the experimental antiviral drug that has shown promise in Covid-19 treatment.

These companies were -- Dr. Reddy's Laboratories Ltd., Zydus Cadila Healthcare Ltd., Biocon company Syngene, Hetero Labs Ltd.; Jubilant Lifesciences; and Cipla Ltd.

Media reports said that Hetero Labs Ltd has also received regulatory approval from DCGI but the drug maker was yet to make it official.

Cipla said it will be commercialising remdesivir through its own facilities and partnered sites.

The drug will be supplied through government and open market channels, to ensure equitable distribution.

For all the latest News, Opinions and Views, download ummid.com App.

Select Language To Read in Urdu, Hindi, Marathi or Arabic.